DBV Technologies SA (NASDAQ:DBVT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.

According to Zacks, “DBV Technologies SA is a biopharmaceutical company. It develops products and immunotherapies for the diagnosis and treatment of various food allergies, including milk and peanut. The Company delivers biological immunoactive compounds, such as allergens, to the immune system by targeting the antigen-presenting cells present in skin. DBV Technologies SA is headquartered in Bagneux, France. “

DBVT has been the subject of a number of other reports. JMP Securities began coverage on shares of DBV Technologies SA in a research report on Monday, September 26th. They set an “outperform” rating and a $47.00 price objective for the company. Leerink Swann reaffirmed a “buy” rating and set a $54.00 price objective on shares of DBV Technologies SA in a research report on Tuesday, August 23rd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $49.57.

Analyst Recommendations for DBV Technologies SA (NASDAQ:DBVT)

DBV Technologies SA (NASDAQ:DBVT) traded up 2.11% during mid-day trading on Tuesday, reaching $36.28. 48,818 shares of the company’s stock traded hands. The stock’s market cap is $1.67 billion. The firm has a 50-day moving average price of $36.04 and a 200-day moving average price of $33.79. DBV Technologies SA has a 1-year low of $22.55 and a 1-year high of $37.98.

Large investors have recently made changes to their positions in the stock. Alliancebernstein L.P. boosted its stake in shares of DBV Technologies SA by 20.3% in the second quarter. Alliancebernstein L.P. now owns 794,220 shares of the company’s stock worth $25,907,000 after buying an additional 133,953 shares during the last quarter. BlackRock Institutional Trust Company N.A. bought a new position in DBV Technologies SA during the second quarter worth approximately $232,000. JPMorgan Chase & Co. increased its position in DBV Technologies SA by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock worth $8,301,000 after buying an additional 15,849 shares during the period. DekaBank Deutsche Girozentrale increased its position in DBV Technologies SA by 12.1% in the second quarter. DekaBank Deutsche Girozentrale now owns 11,100 shares of the company’s stock worth $360,000 after buying an additional 1,200 shares during the period. Finally, Exane Asset Management bought a new position in DBV Technologies SA during the second quarter worth approximately $4,407,000. 47.92% of the stock is owned by institutional investors.

DBV Technologies SA Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Stock Ratings for DBV Technologies SA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA and related stocks with our FREE daily email newsletter.